Development of new therapy for rare motor neuron diseases
Hereditary spastic paraplegias are a group of rare neurodegenerative diseases due to the degeneration of the long axons of cortical motor neurons. Some complex forms of the disease are also characterized by cognitive impairment. C...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
NOVEL ALS MODELS
Developing novel models of Amyotrophic Lateral Sclerosis usi...
100K€
Cerrado
TDP-43
Taming TDP43 High throughput screening for compounds to red...
174K€
Cerrado
SAF2014-57539-R
MODULANDO LIPIDOS EN EL CEREBRO: HACIA UNA TERAPIA PARA LA E...
Cerrado
PHENORAT
EID on the advanced science and technology of rat models for...
925K€
Cerrado
C9ND
C9orf72 mediated neurodegeneration mechanisms and therapeut...
2M€
Cerrado
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Hereditary spastic paraplegias are a group of rare neurodegenerative diseases due to the degeneration of the long axons of cortical motor neurons. Some complex forms of the disease are also characterized by cognitive impairment. Currently, the only available treatments are symptomatic, act on the motor symptoms and do not prevent or delay the disease progression. There is therefore a strong demand of clinicians as well as of patients and their families for the development of any treatment that could delay the onset and/or the progression of the disease. We have developed a genetic mouse model of a complex form of hereditary spastic paraplegia, the SPG11 form that is extremely invalidating as the patients need to be taken in charge by families or specialized institutions. During the ERC Starting Grant program ER-HSP (GA – 311149), we have shown that this model presents both motor and cognitive impairments. We also identified accumulation of some lipid species in lysosomes as a putative therapeutic target to prevent neurodegeneration in this model. With the proof of concept grant, we plan to perform a preclinical trial to identify a possible treatment for this pathology. We have identified two different strategies to decrease the accumulation of lipids in neurons. In vitro assays have shown that both strategies can decrease accumulation of lipids in lysosomes. Importantly, both strategies can be translated into clinical trial in collaboration with industrial partners and represent potential new orphan drugs.